CPT code 0331U designates a Proprietary Laboratory Analyses (PLA) test — Augusta Hematology Optical Genome Mapping from Georgia Esoteric and Molecular (GEM) Laboratory LLC — that applies only to a single manufacturer's laboratory assay. The test employs optical genome mapping (OGM) to identify copy number variants and gene rearrangements associated with hematolymphoid neoplasia, a group of blood and bone–marrow cancers. As a PLA code, 0331U signals a unique clinical assay with implications for molecular diagnosis and care planning in hematologic malignancies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical purpose and typical sites of service, a description of payer coverage scope, and benchmarks where available. The publication summarizes coding context, common billing modifiers, and the significance of a PLA-designated CPT code for laboratory and oncology billing workflows. It also outlines what to expect in terms of clinical application — namely, detection of CNVs and structural rearrangements that can inform diagnosis and therapeutic decision-making in hematolymphoid cancers. Data not provided in the input (such as associated taxonomies, ICD-10 mappings, and payer-specific reimbursement amounts) is noted as not available.